Jceler MV 2 Tablet SR is a combination oral hypoglycemic agent containing Glimepiride (2 mg), Metformin (500 mg), and Voglibose (0.2 mg), indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, which aids in better glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the intestine, leading to a reduction in postprandial hyperglycemia. The sustained-release formulation of Jceler MV 2 Tablet SR ensures a gradual and prolonged release of the active ingredients, promoting better glycemic control with reduced dosing frequency and minimizing gastrointestinal side effects commonly associated with immediate-release formulations. This combination therapy is particularly beneficial for patients inadequately controlled on monotherapy or dual therapy, offering a multifaceted approach to glycemic regulation by targeting different pathophysiological mechanisms of type 2 diabetes. Jceler MV 2 Tablet SR should be used under medical supervision, with regular monitoring of blood glucose levels and renal function, and is contraindicated in patients with severe renal or hepatic impairment, diabetic ketoacidosis, or hypersensitivity to any component.